SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-23-019664
Filing Date
2023-05-09
Accepted
2023-05-09 16:10:21
Documents
9
Period of Report
2023-05-09

Document Format Files

Seq Description Document Type Size
1 6-K q1_2023_-_quarterly_repo.htm 6-K 42372
2 EX-99.1 lmnl-ex99_1.htm EX-99 38277
3 EX-99.2 lmnl-ex99_2.htm EX-99 687195
4 EX-99.3 lmnl-ex99_3.htm EX-99 1328997
5 EX-99.4 lmnl-ex99_4.htm EX-99 20299
6 EX-99.5 lmnl-ex99_5.htm EX-99 21345
7 GRAPHIC img164290822_0.jpg GRAPHIC 12046
8 GRAPHIC img165214343_0.jpg GRAPHIC 12046
9 GRAPHIC img166137864_0.jpg GRAPHIC 12046
  Complete submission text file 0000950170-23-019664.txt   2189817
Mailing Address 440 ARMAND-FRAPPIER BLVD. SUITE 300 LAVAL A8 H7V 4B4
Business Address 231 DUNDAS STREET EAST BELLEVILLE A6 K8N 1E2 450-781-0115
Liminal BioSciences Inc. (Filer) CIK: 0001351172 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39131 | Film No.: 23902063
SIC: 2834 Pharmaceutical Preparations